Uncategorized
DDII UK Conference announces new panels on clinical trial design and early-stage funding

The Drug Discovery Innovators & Investors (DDII) UK Conference will take place at etc.venues Monument, London, on Wednesday 4 November. The conference brings together R&D leaders, lab managers, decision-makers from pharma and biotech companies, industry suppliers, researchers, start-ups, and investors to discuss key challenges in UK drug development.
Two new panels have been confirmed for the day.
Get It Done: Designing Faster, More Effective UK Clinical Trials will examine how technology, policy and infrastructure are enabling better clinical trials in the UK. Panellists will discuss the current strengths, barriers and opportunities for companies conducting clinical trials in the UK. Speakers include Janet Hemingway (Professor, Liverpool School of Tropical Medicine) and Philippa Brown (Head of Development Operations, GSK), with additional speakers to be announced.
Where Is the Money? Funding Early-Stage UK Drug Development in a Difficult Market will take an honest look at where early-stage capital is actually flowing in the UK, and what founders can do when venture capital isn’t an option. The panel brings together Sam Goldsmith (Head of Venture Creation, Cell and Gene Therapy Catapult), Ayokunmi Ajetunmobi (Head of Ventures, Pioneer Group) and Tanya Moore (Investment Principal, Cancer Research Horizons’ Ventures team).
As announced previously, Chris Molloy, CEO of the UK BioIndustry Association, will deliver the conference keynote.
The full-day conference will also feature interactive breakout workshops on topics such as AI in drug discovery, lab automation, spatial biology, and cell and gene therapy.
The programme features structured networking breaks to facilitate meaningful connections. Through the conference app, attendees can review delegate profiles and schedule 1:1 meetings in advance. This approach helps you connect with investors, buyers, collaborators, or clinical trial partners from the start, maximising your time and minimising reliance on chance meetings.
Early bird registration rates are available until 30 September 2026.
The post DDII UK Conference announces new panels on clinical trial design and early-stage funding appeared first on Drug Discovery World (DDW).
Uncategorized
Is the biotech capital of the world moving?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Boston’s biotech identity is under pressure as founders decamp for California, Alzheimer’s researchers uncover more secrets of tau function, and Replimune finally secures a hard-fought FDA approval.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Boston’s biotech identity is under pressure as founders decamp for California, Alzheimer’s researchers uncover more secrets of tau function, and Replimune finally secures a hard-fought FDA approval.
Uncategorized
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study
Vistagen’s repeat-dose anxiety nasal spray can’t beat placebo in mid-stage study
The Phase 2 study was small and was not designed to establish the statistical difference between Vistagen’s drug candidate and placebo, according to Vistagen. The biotech plans to meet with the FDA to determine a registrational path for the asset. Read More
Uncategorized
Opinion: AI won’t enhance physician autonomy. It will further diminish it
Keep your head down. Don’t ask too many questions. Just finish your note and move on.
I heard a version of this command at every level of training and well into my attending practice, from colleagues, seniors, teachers, and administration. Most delivered the advice like it was some sort of hard-won wisdom, though it wasn’t. It was the sound of people who repeated the system’s rules because it felt like control.
Keep your head down. Don’t ask too many questions. Just finish your note and move on.
I heard a version of this command at every level of training and well into my attending practice, from colleagues, seniors, teachers, and administration. Most delivered the advice like it was some sort of hard-won wisdom, though it wasn’t. It was the sound of people who repeated the system’s rules because it felt like control.
-
Fierce Biotech4 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Endpoints News5 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized5 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State